Insulet Is Maintained at Outperform by Raymond James
Insulet Analyst Ratings
Raymond James Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
BTIG Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
Baird Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $280
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $275
Insulet Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $269
Insulet Analyst Ratings
Piper Sandler Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $285
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $234
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $245
Strong Growth and Market Leadership Support Buy Rating for Insulet
Jefferies Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $260
Insulet Stock Buy Rating: FDA Approval Expands Market Reach for Omnipod 5
A Quick Look at Today's Ratings for Insulet(PODD.US), With a Forecast Between $230 to $264
Buy Rating on Insulet: Early FDA Approval and Market Dominance Signal Strong Growth Potential
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
Insulet (PODD) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)